Abstract
Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Current Drug Targets
Title: Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists
Volume: 1 Issue: 3
Author(s): M. A. Khan, R. C. Calvert, M. E. Sullivan, C. S. Thomson, F. H. Mumtaz, R. J. Morgan and D. P. Mikhailidis
Affiliation:
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Abstract: Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Export Options
About this article
Cite this article as:
Khan A. M., Calvert C. R., Sullivan E. M., Thomson S. C., Mumtaz H. F., Morgan J. R. and Mikhailidis P. D., Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists, Current Drug Targets 2000; 1 (3) . https://dx.doi.org/10.2174/1389450003349164
DOI https://dx.doi.org/10.2174/1389450003349164 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance
Current Vascular Pharmacology A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology Type 2 Diabetes: An Atherothrombotic Syndrome
Current Molecular Medicine Depression in Adolescence: From Qualitative Research to Measurement
Adolescent Psychiatry Ultrasound Features of Polycystic Ovaries and Syndrome X: A Pilot Study
Vascular Disease Prevention (Discontinued) Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fetal and Early-Postnatal Developmental Patterns of Obese-Genotype Piglets Exposed to Prenatal Programming by Maternal Over- and Undernutrition
Endocrine, Metabolic & Immune Disorders - Drug Targets Immune Response to Native Lipoproteins Induces Visceral Obesity and Aortic Wall Injury in Rats: The Role of Testosterone
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design The Metabolic Fate of Apple Polyphenols in Humans
Current Nutrition & Food Science Discovery and Pre-clinical Development of Antithrombotics from Hematophagous Invertebrates
Current Medicinal Chemistry - Cardiovascular & Hematological Agents